These medications have become a game-changer for the treatment of both diabetes and obesity
Tirzepatide, sold under the brand name Mounjaro (for diabetes) and Zepbound (for weight loss), is a newer medication that targets two hormones instead of just one
This is consistent with the broader class of GLP-1 receptor agonists, where gastrointestinal symptoms particularly nausea, vomiting, and diarrhoea are well-recognised and expected effects
GLP-1 Medications Available Through Ro Clinical Evidence and Weight Loss Results How the Ro Body Program Works: Step-by-Step Pricing and Membership Costs Insurance Coverage and Navigation Support Zepbound Vials Through LillyDirect Integration Complete FDA Safety Information Member Survey Results and Real Experiences Lifestyle Support and Coaching Services Eligibility Requirements and State Availability Frequently Asked Questions How Ro Compares to Other Telehealth Options Getting Started with Ro Weight Loss Executive Summary: Ro Weight Loss Review 2025 - Key Takeaways Quick Overview of the Ro Body Program According to information published on ro.co as of November 2025, the Ro Body Program provides telehealth-based access to FDA-approved GLP-1 (glucagon-like peptide-1) receptor agonist medications for weight management
[10] [11] Patients prescribed GLP-1 medications receive comprehensive support, including education about administration technique, management of common side effects (such as nausea, which often improves over time), and monitoring for efficacy and safety
Some patients experience nausea, constipation, reflux, fatigue, appetite suppression, diarrhea, abdominal discomfort, dizziness, or difficulty eating enough protein
